Related Experiment Video

Updated: Oct 2, 2026

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica

Published on: April 12, 2019

CEA and CA 549 in serum and pleural fluid of patients with pleural effusion

Luis Hernández¹, Antonia Espasa, Cleofé Fernández

¹Servicios de Neumología, Hospital General Universitario de Alicante, 03010, Spain. hernandez_lui@gva.es

Lung Cancer (Amsterdam, Netherlands)

|March 14, 2002

Abstract

Background:

The determination of the pleural fluid (PF) carcinoembryonic antigen (CEA) concentration has proved helpful in the differentiation between pleural effusions (PE) of malignant and benign origin. The present study was designed to prospectively compare the utility of CEA with that of a recently introduced tumour marker, carbohydrate antigen 549 (CA 549).

Patients And Methods:

In 383 consecutive patients referred for thoracentesis (130 malignant and 253 benign), pleural and serum levels of CEA and CA 549 were, respectively, determined by enzyme immunoassay (EIA) and immunoradiometric assay (IRMA).

Results:

CEA and CA 549 showed a high specificity for malignancy in serum (97 and 96%, respectively) and PF (98 and 99%). The serum sensitivity was 33% for CEA and 47% for CA 549 while in PF was 49 and 54%, respectively. The area under the curve of CA 549 (0.78) was significantly larger than that of CEA (0.66) in serum (P < 0.005) and in PF (0.83 and 0.75, respectively, P < 0.02) as well. CA 549 showed a higher sensitivity (P < 0.001) than CEA for ovarian tumours. In PF, the accuracy of the combination of both markers was higher than that of any individual marker, although the difference was only significant with respect to CEA (P < 0.02).

Conclusions:

The results of the present study show that a new tumour marker CA 549 is at least similar in terms of sensitivity and specificity to CEA in the evaluation of patients with PE of unknown cause.

More Related Videos

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca²⁺-imaging and Degranulation Assays

Published on: July 4, 2018

Related Concept Videos

Pleural Effusion II: Symptoms and Management

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:

Pleural Effusion I: Introduction

Pleural Effusion I: Introduction

Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's criteria,...

Endoscopic Studies II: Thoracocentesis

Endoscopic Studies II: Thoracocentesis

Thoracentesis(Thoracocentesis), commonly known as pleural tap, is a medical procedure where a 22 gauge needle is inserted into the pleural space, the area between the lung and chest wall. This procedure is commonly performed to diagnose or treat various respiratory disorders.
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...

Pleura of the Lungs

Pleura of the Lungs

The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pleural Disorders: Types and Brief Description

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:

Articles linked to this work by shared authors, journal, and citation graph.

Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five-Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease.

Alimentary pharmacology & therapeutics·2026

Effect of external evaluation and training on the incomplete resection rate in cold snare polypectomies for colonic lesions <10 mm: a prospective Spanish study (POLIPEVA).

Clinical endoscopy·2026

In vitro susceptibility testing of aztreonam-avibactam against predominantly NDM-producing Enterobacterales in Peru.

Microbiology spectrum·2026

Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study.

Journal of blood medicine·2026

Medical deserts in gastroenterology: A nationwide study of specialists perceptions in a universal public healthcare system.

Gastroenterologia y hepatologia·2026

Real-World Clinical and Economic Consequences of Next-Generation Anaplastic Lymphoma Kinase-Positive (ALK +) Tyrosine Kinase Inhibitors (TKIs) in Patients with TKI-Naïve ALK + Metastatic Non-Small Cell Lung Cancer in the United States.

Advances in therapy·2026

See all related articles